Quercetin improves epithelial regeneration from airway basal cells of COPD patients

Respir Res. 2024 Mar 11;25(1):120. doi: 10.1186/s12931-024-02742-0.

Abstract

Background: Airway basal cells (BC) from patients with chronic obstructive pulmonary disease (COPD) regenerate abnormal airway epithelium and this was associated with reduced expression of several genes involved in epithelial repair. Quercetin reduces airway epithelial remodeling and inflammation in COPD models, therefore we examined whether quercetin promotes normal epithelial regeneration from COPD BC by altering gene expression.

Methods: COPD BC treated with DMSO or 1 µM quercetin for three days were cultured at air/liquid interface (ALI) for up to 4 weeks. BC from healthy donors cultured at ALI were used as controls. Polarization of cells was determined at 8 days of ALI. The cell types and IL-8 expression in differentiated cell cultures were quantified by flow cytometry and ELISA respectively. Microarray analysis was conducted on DMSO or 1 µM quercetin-treated COPD BC for 3 days to identify differentially regulated genes (DEG). Bronchial brushings obtained from COPD patients with similar age and disease status treated with either placebo (4 subjects) or 2000 mg/day quercetin (7 subjects) for 6 months were used to confirm the effects of quercetin on gene expression.

Results: Compared to placebo-, quercetin-treated COPD BC showed significantly increased transepithelial resistance, more ciliated cells, fewer goblet cells, and lower IL-8. Quercetin upregulated genes associated with tissue and epithelial development and differentiation in COPD BC. COPD patients treated with quercetin, but not placebo showed increased expression of two developmental genes HOXB2 and ELF3, which were also increased in quercetin-treated COPD BC with FDR < 0.001. Active smokers showed increased mRNA expression of TGF-β (0.067) and IL-8 (22.0), which was reduced by 3.6 and 4.14 fold respectively after quercetin treatment.

Conclusions: These results indicate that quercetin may improve airway epithelial regeneration by increasing the expression of genes involved in epithelial development/differentiation in COPD.

Trial registration: This study was registered at ClinicalTrials.gov on 6-18-2019. The study number is NCT03989271.

Keywords: Chronic obstructive pulmonary disease; ELF3; Goblet cell metaplasia; HOXB2.

MeSH terms

  • Bronchi / metabolism
  • Cells, Cultured
  • Dimethyl Sulfoxide / metabolism
  • Dimethyl Sulfoxide / pharmacology
  • Epithelial Cells / metabolism
  • Homeodomain Proteins / metabolism
  • Homeodomain Proteins / pharmacology
  • Humans
  • Interleukin-8 / metabolism
  • Pulmonary Disease, Chronic Obstructive* / diagnosis
  • Pulmonary Disease, Chronic Obstructive* / drug therapy
  • Pulmonary Disease, Chronic Obstructive* / genetics
  • Quercetin* / metabolism
  • Quercetin* / pharmacology
  • Quercetin* / therapeutic use
  • Transcription Factors / metabolism

Substances

  • Quercetin
  • Interleukin-8
  • Dimethyl Sulfoxide
  • HOXB2 protein, human
  • Transcription Factors
  • Homeodomain Proteins

Associated data

  • ClinicalTrials.gov/NCT03989271